We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00262093
Recruitment Status : Unknown
Verified November 2005 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : December 6, 2005
Last Update Posted : March 20, 2007
Information provided by:

Study Description
Brief Summary:
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Condition or disease

Detailed Description:

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.

We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Study Design

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
Study Start Date : November 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Every delivery

Exclusion Criteria:

  • Preeclampsia or pregnancy induced hypertension
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262093

Contact: Yuval Bdolah, MD, MSc 972-2-5844111 ybdolah@hadassah.org.il
Contact: Hadas Lemberg, PhD 972-2-6777572 lhadas@hadassah.org.il

Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91240
Contact: Arik Tzukert, DMD    972 2 6776095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    972 2 6777572    lhadas@hadassah.org.il   
Principal Investigator: Yuval Bdolah, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Beth Israel Deaconess Medical Center
Principal Investigator: Yuval Bdolah, MD, MSc Hadassah-Hebrew University Medical School
More Information

ClinicalTrials.gov Identifier: NCT00262093     History of Changes
First Posted: December 6, 2005    Key Record Dates
Last Update Posted: March 20, 2007
Last Verified: November 2005

Keywords provided by Hadassah Medical Organization:

Additional relevant MeSH terms:
Hypertension, Pregnancy-Induced
Pregnancy Complications